OR WAIT null SECS
October 30, 2023
PENBRAYA combines components from two meningococcal vaccines, Trumenba and Nimenrix.
October 26, 2023
The treatment has received Priority Review designation, as well as FDA Breakthrough Therapy designation and Orphan Drug designation.
October 20, 2023
The designation will grant Lisata EU marketing exclusivity for 10 years after approval and protocol assistance from EMA.
The spinal muscular atrophy treatment, currently marketed by Roche, generated $1.2 billion in sales in 2022.
October 18, 2023
These results will provide insights from more than 250 global pharma executives, including discoveries such as pharma confidence dipping below the record scores of 2022, although it has remained extremely resilient despite wider macro uncertainly, according to the press release.
Spark Therapeutics and SpliceBio have formed a collaboration to develop a gene therapy that can treat an inherited retinal disease.
October 15, 2023
When considering manufacturing and the growth of drug formulation, it is evident that there has been change and many new advancements introduced to make processes more efficient.
October 13, 2023
This approval builds on a previous approval of the combination therapy for patients with BRAF V600E- or V600K-mutant unresectable or metastatic melanoma.
October 12, 2023
Mirati’s focus on breakthrough cancer treatments will bolster Bristol Myers Squibb’s oncology portfolio.
Salipro Biotech and Icosagen have entered into a multi-target collaboration to discover and characterize monoclonal antibodies.